IL83192A - Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies - Google Patents

Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies

Info

Publication number
IL83192A
IL83192A IL83192A IL8319287A IL83192A IL 83192 A IL83192 A IL 83192A IL 83192 A IL83192 A IL 83192A IL 8319287 A IL8319287 A IL 8319287A IL 83192 A IL83192 A IL 83192A
Authority
IL
Israel
Prior art keywords
host cells
antibodies
proteins
preparation
expression vectors
Prior art date
Application number
IL83192A
Other languages
English (en)
Other versions
IL83192A0 (en
Original Assignee
Gist Brocades Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868617594A external-priority patent/GB8617594D0/en
Priority claimed from GB868630699A external-priority patent/GB8630699D0/en
Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv
Publication of IL83192A0 publication Critical patent/IL83192A0/xx
Publication of IL83192A publication Critical patent/IL83192A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL83192A 1986-07-18 1987-07-14 Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies IL83192A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868617594A GB8617594D0 (en) 1986-07-18 1986-07-18 Preparation of biologically active proteins
GB868630699A GB8630699D0 (en) 1986-12-23 1986-12-23 Preparation of biologically active proteins

Publications (2)

Publication Number Publication Date
IL83192A0 IL83192A0 (en) 1987-12-31
IL83192A true IL83192A (en) 1992-11-15

Family

ID=26291059

Family Applications (1)

Application Number Title Priority Date Filing Date
IL83192A IL83192A (en) 1986-07-18 1987-07-14 Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies

Country Status (9)

Country Link
EP (1) EP0253455A1 (xx)
JP (1) JPS63313587A (xx)
AU (1) AU620315B2 (xx)
DK (1) DK374087A (xx)
FI (1) FI873162A (xx)
IL (1) IL83192A (xx)
NO (1) NO872932L (xx)
NZ (1) NZ221119A (xx)
PT (1) PT85349B (xx)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
AU591671B2 (en) * 1985-04-11 1989-12-14 Children's Medical Center Corporation Von willebrand factor
US5278066A (en) * 1985-08-09 1994-01-11 Gist-Brocades Nv Molecular cloning and expression of gene encoding lipolytic enzyme
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US5830735A (en) * 1987-03-06 1998-11-03 Gist-Brocades Nv Method for producing lipolytic enzymes using transformed Pseudomonas
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU627150B2 (en) * 1987-06-12 1992-08-20 Immuno Ag Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) * 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
CA1340740C (en) * 1987-12-08 1999-09-14 Eileen R. Mulvihill Co-expression in eukaryotic cells
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
GB2214508A (en) * 1988-01-27 1989-09-06 Bayer Ag Plasmid vector for the efficient expression of foreign genes fused with newly conceived transcriptional and translational signal sequences.
BR9006818A (pt) * 1989-06-29 1991-08-06 Gist Brocades Nv Amilases microbianas mutantes com maior estabilidade termica,acida e/ou alcalina
DD298055A5 (de) * 1989-09-14 1992-02-06 ����������@�����������@���Kk�� Methode und nuetzlicher apparat zur darstellung pharmazeutischer zusammensetzungen
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
GB9907461D0 (en) 1999-03-31 1999-05-26 King S College London Neurite regeneration
EP0965597A4 (en) * 1996-12-27 2003-01-08 Mochida Pharm Co Ltd CELL MEMBRANE EFFECTIVE DRUGS
US8372620B2 (en) 1998-12-23 2013-02-12 Dupont Nutrition Biosciences Aps Bacterial xylanases
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
AU2000277798B2 (en) 2000-09-21 2006-06-22 Basf Aktiengesellschaft Talaromyces xylanases
DK1339837T3 (da) 2000-12-07 2008-06-09 Dsm Ip Assets Bv Prolyl-endoprotease fra Aspergillus Niger
CA2706364A1 (en) 2000-12-07 2002-06-13 Dsm Ip Assets B.V. Method for the prevention or reduction of haze in beverages
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
WO2003013244A1 (en) 2001-08-03 2003-02-20 The Government Of The United State Of America, As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
EP1511835B9 (en) 2002-06-07 2015-02-25 DSM IP Assets B.V. Improved method for the prevention or reduction of haze in beverages
TWI328612B (en) 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2007060247A2 (en) 2005-11-28 2007-05-31 Dsm Ip Assets B.V. Enzyme preparations yielding a clean taste
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
NZ578882A (en) 2007-02-20 2012-01-12 Dsm Ip Assets Bv Sialidase from the fungus Penicilium chrysogenum
ES2608033T3 (es) 2007-03-22 2017-04-05 Dsm Ip Assets B.V. Nuevas lisil oxidasas
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
WO2011101339A2 (en) 2010-02-18 2011-08-25 Dsm Ip Assets B.V. Fermentation broth and filtration filter cake and uses thereof
WO2012007446A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Use of a mutarotase in the production of dried powders
WO2012007445A1 (en) 2010-07-13 2012-01-19 Dsm Ip Assets B.V. Mutarotase in crystallization

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000028I1 (de) * 1984-01-12 2004-09-30 Chiron Corp F}r Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen.
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta

Also Published As

Publication number Publication date
NZ221119A (en) 1990-08-28
AU7575487A (en) 1988-01-21
EP0253455A1 (en) 1988-01-20
NO872932D0 (no) 1987-07-14
FI873162A (fi) 1988-01-19
JPS63313587A (ja) 1988-12-21
AU620315B2 (en) 1992-02-20
IL83192A0 (en) 1987-12-31
DK374087D0 (da) 1987-07-17
PT85349B (pt) 1990-04-30
PT85349A (en) 1987-08-01
NO872932L (no) 1988-01-19
FI873162A0 (fi) 1987-07-17
DK374087A (da) 1988-01-19

Similar Documents

Publication Publication Date Title
IL83192A0 (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
FI900267A0 (fi) Menetelmä T-soluavustaja-aktiivisuutta omaavien peptidien valmistamiseksi
CA2220515A1 (en) Process for producing erythropoietin containing no animal proteins
EP0318296A3 (en) Interleukin-1 receptors
GB8610551D0 (en) Polypeptide & protein derivatives
HUP0000317A3 (en) Process for the preparation of recombinant proteins in e.coli by high cell density fermentation
AU3192889A (en) T cell activation markers
AU6733487A (en) Mammalian interleukin-4
EP0219106A3 (en) Polypeptides that elicit antibodies against aids virus
EP0151246A3 (en) Polypeptide inhibitor of the activity of alpha-amylase, process for its preparation, its use, and pharmaceutical preparations
IT8423082A0 (it) Impianto di controllo eprocedimento per il riempimento ponderale di bottiglie, flaconi esimili.
IL90334A0 (en) Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides
PH31198A (en) Protein recognized by antibodies raised against native P28 of schitosoma mansoni.
AU3608589A (en) Expression vectors for the preparation of infused proteins in microorganisms
AU582416B2 (en) Polypeptide secretion-causing vector, microorganisms transformed by said vector, and process for preparing polypeptide using said microorganisms
AU7265087A (en) Animal cell transformant, method for obtaining the transformant and method for producing desired foreign gene product by using the transformant
ZA875267B (en) Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies
IE871932L (en) Method for the preparation of proteins with factor viii¹activity by microbial host cells, expression vectors, host¹cells, antibodies
AU6521186A (en) Lytic viruses as expression vectors, host cell containing same and process for protein production
EP0264118A3 (en) Novel method for preparing proteins
AU561649B2 (en) Antibodies to proteins
NO178036C (no) Fremgangsmåte for fremstilling av fusjonsproteiner, genstruktur, vektorer streptomycetceller og fusjonsproteinene
AU7851387A (en) Protein kinase c enzymes
AU538170B2 (en) Modified protein to mould an enzyme type molecule
LTIP1543A (en) Process for enzymatic decomposition of recombinant proteins by means of iga-protease, fused protein, recombinant dna, cell

Legal Events

Date Code Title Description
RH Patent void